• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

腺相关病毒作为肝脏靶向性基因递送载体:聚焦于脂蛋白代谢

Adeno-associated viruses as liver-directed gene delivery vehicles: focus on lipoprotein metabolism.

作者信息

Lagor William R, Johnston Julie C, Lock Martin, Vandenberghe Luk H, Rader Daniel J

机构信息

Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.

出版信息

Methods Mol Biol. 2013;1027:273-307. doi: 10.1007/978-1-60327-369-5_13.

DOI:10.1007/978-1-60327-369-5_13
PMID:23912992
Abstract

Adeno-associated viral vectors have proven to be excellent gene delivery vehicles for somatic overexpression. These viral vectors can efficiently and selectively target the liver, which plays a central role in lipoprotein metabolism. Both liver-expressed as well as non-hepatic secreted proteins can be easily examined in different mouse models using this approach. The dosability of adeno-associated viral (AAV) vectors, as well as their potential for long-term expression, makes them an excellent choice for assessing gene function in vivo. This section will cover the use of AAV to study lipoprotein metabolism-including vector design, virus production and purification, and viral delivery, as well as monitoring of transgene expression and resulting phenotypic changes. Practical information is provided to assist the investigator in designing, interpreting, and troubleshooting experiments.

摘要

腺相关病毒载体已被证明是用于体细胞过表达的优秀基因递送载体。这些病毒载体能够高效且选择性地靶向肝脏,而肝脏在脂蛋白代谢中起核心作用。使用这种方法,可以在不同的小鼠模型中轻松检测肝脏表达的蛋白以及非肝脏分泌的蛋白。腺相关病毒(AAV)载体的可定量性及其长期表达的潜力,使其成为在体内评估基因功能的理想选择。本节将介绍使用AAV研究脂蛋白代谢的相关内容,包括载体设计、病毒生产与纯化、病毒递送,以及转基因表达监测和由此产生的表型变化。还提供了实用信息,以协助研究人员设计、解释实验并解决实验故障。

相似文献

1
Adeno-associated viruses as liver-directed gene delivery vehicles: focus on lipoprotein metabolism.腺相关病毒作为肝脏靶向性基因递送载体:聚焦于脂蛋白代谢
Methods Mol Biol. 2013;1027:273-307. doi: 10.1007/978-1-60327-369-5_13.
2
AAV6 Vector Production and Purification for Muscle Gene Therapy.用于肌肉基因治疗的腺相关病毒6型载体的生产与纯化
Methods Mol Biol. 2018;1687:257-266. doi: 10.1007/978-1-4939-7374-3_18.
3
Liver-directed gene expression using recombinant AAV 2/8 vectors--a tolerogenic strategy for gene delivery?
Discov Med. 2010 Jun;9(49):519-27.
4
Pre-existing immunity to adeno-associated virus (AAV)2 limits transgene expression following intracerebral AAV2-based gene delivery in a 6-hydroxydopamine model of Parkinson's disease.在帕金森病的6-羟基多巴胺模型中,预先存在的对腺相关病毒(AAV)2的免疫力限制了基于AAV2的脑内基因递送后的转基因表达。
J Gene Med. 2014 Sep-Oct;16(9-10):300-8. doi: 10.1002/jgm.2779.
5
Adeno-associated viral vectors for correction of inborn errors of metabolism: progressing towards clinical application.腺相关病毒载体用于代谢性遗传病的基因治疗:向临床应用推进。
Curr Pharm Des. 2011;17(24):2500-15. doi: 10.2174/138161211797247569.
6
Recombinant adeno-associated virus as delivery vector for gene therapy--a review.重组腺相关病毒作为基因治疗的递送载体——综述
Stem Cells Dev. 2004 Feb;13(1):133-45. doi: 10.1089/154732804773099335.
7
Persistent liver expression of murine apoA-l using vectors based on adeno-associated viral vectors serotypes 5 and 1.使用基于5型和1型腺相关病毒载体的载体在小鼠肝脏中持续表达载脂蛋白A-Ⅰ
Atherosclerosis. 2006 May;186(1):65-73. doi: 10.1016/j.atherosclerosis.2005.07.009. Epub 2005 Aug 15.
8
Purification of recombinant adeno-associated virus vectors by column chromatography and its performance in vivo.通过柱色谱法纯化重组腺相关病毒载体及其体内性能
Hum Gene Ther. 2000 Oct 10;11(15):2079-91. doi: 10.1089/104303400750001390.
9
Vectrology of adeno-associated viruses (AAV).腺相关病毒(AAV)的载体学
Med Wieku Rozwoj. 2013 Jul-Sep;17(3):202-6.
10
Myocardial gene transfer and long-term expression following intracoronary delivery of adeno-associated virus.腺相关病毒冠状动脉内递送后的心肌基因转移和长期表达
J Gene Med. 2005 Mar;7(3):316-24. doi: 10.1002/jgm.665.

引用本文的文献

1
Speg interactions that regulate the stability of excitation-contraction coupling protein complexes in triads and dyads.三联体和二联体中调节兴奋-收缩偶联蛋白复合物稳定性的 Speg 相互作用。
Commun Biol. 2023 Sep 14;6(1):942. doi: 10.1038/s42003-023-05330-y.
2
Adeno-Associated virus 8 delivers an immunomodulatory peptide to mouse liver more efficiently than to rat liver.腺相关病毒 8 向小鼠肝脏传递免疫调节肽的效率高于向大鼠肝脏传递。
PLoS One. 2023 Apr 11;18(4):e0283996. doi: 10.1371/journal.pone.0283996. eCollection 2023.
3
disruption with AAV-CRISPR potently lowers plasma apo(a) in transgenic mouse model: A proof-of-concept study.
在转基因小鼠模型中,腺相关病毒-成簇规律间隔短回文重复序列(AAV-CRISPR)干扰可有效降低血浆载脂蛋白(a):一项概念验证研究。
Mol Ther Methods Clin Dev. 2022 Oct 13;27:337-351. doi: 10.1016/j.omtm.2022.10.009. eCollection 2022 Dec 8.
4
In Vivo Gene Editing in Lipid and Atherosclerosis Research.体内基因编辑在脂质和动脉粥样硬化研究中的应用
Methods Mol Biol. 2022;2419:673-713. doi: 10.1007/978-1-0716-1924-7_42.
5
Targeting the locus for liver-directed gene therapy.靶向肝脏定向基因治疗的基因座。
Mol Ther Methods Clin Dev. 2021 Apr 24;21:656-669. doi: 10.1016/j.omtm.2021.04.011. eCollection 2021 Jun 11.
6
Depletion of essential isoprenoids and ER stress induction following acute liver-specific deletion of HMG-CoA reductase.急性肝特异性敲除 HMG-CoA 还原酶后必需异戊二烯的耗竭和内质网应激的诱导。
J Lipid Res. 2020 Dec;61(12):1675-1686. doi: 10.1194/jlr.RA120001006. Epub 2020 Oct 27.
7
TFEB regulates murine liver cell fate during development and regeneration.TFEB 调节发育和再生过程中鼠类肝细胞的命运。
Nat Commun. 2020 May 18;11(1):2461. doi: 10.1038/s41467-020-16300-x.
8
AAV-CRISPR Gene Editing Is Negated by Pre-existing Immunity to Cas9.AAV-CRISPR 基因编辑被 Cas9 预先存在的免疫所否定。
Mol Ther. 2020 Jun 3;28(6):1432-1441. doi: 10.1016/j.ymthe.2020.04.017. Epub 2020 Apr 19.
9
Novel lecithin: cholesterol acyltransferase-based therapeutic approaches.新型卵磷脂:胆固醇酰基转移酶为基础的治疗方法。
Curr Opin Lipidol. 2020 Apr;31(2):71-79. doi: 10.1097/MOL.0000000000000673.
10
Gene Delivery in Lipid Research and Therapies.脂质研究与治疗中的基因递送
Methodist Debakey Cardiovasc J. 2019 Jan-Mar;15(1):62-69. doi: 10.14797/mdcj-15-1-62.